Symptomatic neonatal hepatitis A disease from a virus variant acquired in utero

Viral Hepatitis in Pregnancy: ACOG Clinical Practice Guideline No. 6

PURPOSE

The purpose of this document is to describe the specific types of viral hepatitis, their implications during pregnancy, the risk of perinatal transmission, and issues related to both treatment and prevention of infection.

TARGET POPULATION

Pregnant or postpartum women and individuals who screen positive for viral hepatitis infection. The onset of these conditions may have predated the perinatal period or may have occurred for the first time in pregnancy or the first year postpartum.

METHODS

This guideline was developed using an a priori protocol in conjunction with a writing team consisting of one specialist in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Guidelines-Obstetrics and one external subject matter expert. ACOG medical librarians completed a comprehensive literature search for primary literature within Cochrane Library, Cochrane Collaboration Registry of Controlled Trials, EMBASE, PubMed, and MEDLINE. Studies that moved forward to the full-text screening stage were assessed by two authors from the writing team based on standardized inclusion and exclusion criteria. Included studies underwent quality assessment, and a modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) evidence-to-decision framework was applied to interpret and translate the evidence into recommendation statements.

RECOMMENDATIONS

This Clinical Practice Guideline includes recommendations on hepatitis B virus and hepatitis C virus screening in pregnancy; prepregnancy, antepartum, intrapartum, and postpartum management for patients with hepatitis B virus infection or hepatitis C virus infection; management of accidental and occupational exposure to hepatitis B virus or hepatitis C virus in pregnant health care workers; and hepatitis A virus and hepatitis B virus vaccination in pregnancy. Recommendations are classified by strength and evidence quality. Ungraded Good Practice Points are included to provide guidance when a formal recommendation could not be made because of inadequate or nonexistent evidence.

No evidence of intrauterine transmission of hepatitis A virus from a mother to a premature infant

AIM

To determine whether or not an intrauterine transmission of hepatitis A virus (HAV) occurred from an infected mother to her premature infant delivered by caesarean section.

METHODS

The mother and her child were tested for HAV by serology and reverse transcription PCR.

RESULTS

An outbreak of HAV infection was seen among children and a 33-year-old day-care teacher, pregnant in third trimester, at a day-care centre in southern Sweden. Due to premature labour and diminished foetal movements a caesarean section was performed and a premature girl in gestational weeks 33 + 1 was born. During the 3-week postnatal hospitalization period the child presented no clinical symptoms of HAV infection and anti-HAV IgM antibodies remained undetectable at day 14 and 109 after birth. Furthermore HAV RNA remained undetectable by reverse transcription PCR in the child's blood at birth and in throat and faeces for the first 3 and 4 weeks of life respectively. HAV RNA in the mother's blood was detected at 6 days prior to and at 17 days after delivery. HAV RNA was undetectable in breast milk when tested on day 3 after delivery.

CONCLUSION

There was no evidence of intrauterine transmission of hepatitis A virus from a viraemic mother to her premature child delivered at gestational week 33 + 1 by caesarean section.

Hepatitis A vaccine

Hepatitis A is an infectious disease frequently reported in the United States. An average of 26,000 cases were reported each year during 1980 to 1999; probably 3 times as many occurred. Hepatitis A vaccines provide a powerful new prevention tool. The 2 inactivated hepatitis A vaccines available as pediatric and adult formulations in the United States and in many other countries are safe, immunogenic, and efficacious. A single dose provides excellent short-term protection; the second dose is thought to be important for long-term protection. Because hepatitis A virus (HAV) is excreted in high concentrations in the stool, the principal mode of transmission is person-to-person by the fecal-oral route, most commonly among household and sexual contacts of people with HAV infection. Children can be important in transmission because they frequently have unrecognized or asymptomatic infection. Implementation of recommendations for routine hepatitis A vaccination of children living in areas with consistently elevated hepatitis A rates appears to be resulting in dramatic declines in the overall incidence of the disease. Improved vaccination coverage and continued monitoring of incidence rates are needed to determine the overall long-term impact of this strategy.